One dividend growth stock I’d buy and one I’d sell

Roland Head compares a new arrival with an established player.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Toilet rolls are big business. Accrol Group Holdings (LSE: ACRL) sold £135.1m of tissue products last year, 14.2% more than during the previous year. Pre-tax profit rose by 29.3% to £7.4m. Shareholders will receive a final dividend of 4p, giving a total payout of 6p for the year just ended. That gives a dividend yield of 3.9% at the current share price of 153p.

Accrol describes itself as a tissue converter, which means that it converts so-called primary rolls of tissue from paper mills into products such as loo paper, tissues and kitchen roll. The company’s main business is producing and supplying branded and private label products for supermarkets. A particular focus is the discount sector, where it has a market share of more than 50%.

It’s tempting to think that this recently-floated stock could become an attractive income growth play.

Why I wouldn’t buy

Last year’s financial performance was very solid. But there are a number of things about this business which concern me. One risk, in my view, is that the firm’s customers will never allow it to be too profitable. The company’s gross profit margin fell from 29.2% to 27.9% last year. The group’s operating margin, which includes a wider range of costs and expenses, fell from 10.1% to 7.8%.

In today’s results, chief executive Steve Crossley comments that input costs are rising. He notes that “we continue to seek inflation recovery”. According to Mr Crossley, retailers are increasing their prices “slower than expected”. These comments seem to confirm my view that this business’s customers will use their negotiating power to keep prices down. I suspect it will be difficult for Accrol to regain this lost margin.

On that basis, I’d argue that on a forecast P/E of 11.5, Accrol stock is probably fairly priced.

One I would buy

For consumer goods firms, the secret to pricing power lies in having strong brands. One company which understands this is FTSE 100 group Reckitt Benckiser Group (LSE: RB), which owns brands including Dettol, Nurofen, Harpic and Strepsils.

Producing these branded goods isn’t necessarily any more expensive than producing own-label products for supermarkets. However, their premium positioning and customer appeal means that prices and profit margins tend to be higher.

Reckitt has generated an average operating margin of 24% over the last five years. The group generates a huge amount of free cash flow, enabling it to invest in new products and acquisitions without excessive levels of debt. Although the group’s recent $17.9bn acquisition of Mead Johnson will result in raised debt levels, I’m confident its cash generation will enable it to repay this additional borrowing promptly.

The stock has fallen by about 5% from the all times high of £81 per share seen at the start of June. Reckitt was also hit by a recent cyber-attack and said the disruption this has caused is expected to reduce full-year sales growth from 3% to 2%.

In my view, this is just a short-term blip for this impressive growth business. Although the stock is expensive on 22 times forecast earnings, I think the firm’s defensive qualities mean that it’s worth considering as a long-term buy.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any shares mentioned. The Motley Fool UK has recommended Reckitt Benckiser. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

1 FTSE 250 share that can soar like the Rolls-Royce share price

The Rolls-Royce share price has grown almost fivefold since the start of 2023. Muhammad Cheema takes a look at a…

Read more »

Close-up of British bank notes
Investing Articles

How I’d invest my £20K ISA allowance to target £1,380 of passive income annually

Christopher Ruane explains the approach he'd take to try to generate income of almost £1,400 next year -- and annually…

Read more »

Hand of a mature man opening a safety deposit box.
Investing Articles

2 super-safe dividend stocks that have been paying passive income for decades

Income from stocks is never nailed on. But there are a handful of UK dividend stocks that have been incredibly…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

Diageo: time for me to sell this FTSE 100 stock before 5 November?

As the US election draws ever closer, our writer is wondering what to do with this struggling FTSE 100 stock…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Trading at 28 times earnings, is there value in this FTSE 250 stock?

Our writer Ken Hall takes a deep dive into a recent FTSE 250 addition that has rocketed higher since its…

Read more »

Market Movers

Amazon stock shoots higher after earnings! Here’s what I think happens next

Jon Smith explains why Amazon stock has jumped following the latest results and why the outlook could keep the rally…

Read more »

Couple working from home while daughter watches video on smartphone with headphones on
Investing Articles

After jumping 10% this morning is this hated FTSE 100 stock suddenly a screaming buy for me?

Harvey Jones rejected any thought of buying this former FTSE 100 darling in August but after some positive news should…

Read more »

artificial intelligence investing algorithms
Investing Articles

Down 12% in a month and yielding 10.7%! Is this November’s best passive income stock?

Harvey Jones has been building his stake in this ultra-high-yielding FTSE 100 passive income stock. And with its shares dipping…

Read more »